68镓PSMA示踪剂对生化复发前列腺癌患者管理的影响
该系统综述与荟萃分析纳入20项研究共2026例患者,评估68Ga-PSMA示踪剂对生化复发前列腺癌患者管理的影响。汇总分析显示,53%(95%CI 46-60)的患者管理发生改变,早期生化复发(PSA<0.5 ng/mL)患者为51%(95%CI 34-67),PET阳性率为68%(95%CI 59-78)。结论认为68Ga-PSMA示踪剂改变了超过半数生化复发患者的管理,包括早期生化复发者。
要点
- 68Ga-PSMA示踪剂使53%的生化复发前列腺癌患者管理发生改变。
- 早期生化复发(PSA<0.5 ng/mL)患者管理改变比例仍达51%。
- 管理改变以跨模式转变为主(42%),模式内改变为17%。
核心结论
- 68Ga-PSMA示踪剂改变了超过半数生化复发前列腺癌患者的管理,包括早期生化复发者。
- 68Ga-PSMA示踪剂可能用于指导生化复发患者的个体化治疗,尤其是早期生化复发者。
研究设计与样本
- 纳入20项报告生化复发患者使用68Ga-PSMA示踪剂后管理改变比例的研究,共2026例患者。
- 使用QUADAS-2工具评估纳入研究质量,采用随机效应模型汇总管理改变比例。
主要发现
- 生化复发患者管理改变的汇总比例为53%(95%CI 46-60)。
- 早期生化复发(PSA<0.5 ng/mL)患者管理改变的汇总比例为51%(95%CI 34-67)。
- 生化复发患者PET阳性率的汇总值为68%(95%CI 59-78)。
临床怎么用
- 68Ga-PSMA示踪剂可用于指导生化复发前列腺癌患者的个体化治疗决策。
- 对早期生化复发(PSA<0.5 ng/mL)患者亦可考虑使用68Ga-PSMA示踪剂评估以指导管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the impact of 68 Gallium prostate-specific membrane antigen (68 Ga-PSMA) tracers on the management of prostate cancer (PCa) patients with biochemical recurrence (BCR) by conducting a systematical review and meta-analysis. MATERIALS AND METHODS: We performed a literature search of the PubMed, Embase and Web of Science databases up to 29 October 2019. We included studies that reported the proportion of patients whose management changed after 68 Ga-PSMA tracers were used in patients with BCR. We used the Quality Assessment of Diagnostic Accuracy Studies-2 tool to evaluate the quality of the included studies. The proportion of patients with management changes were pooled using a random-effects model. Subgroup analyses and meta-regression analyses were performed to explore the source of heterogeneity. A Sankey diagram was used to show treatment change from before to after the use of 68 Ga-PSMA tracers. RESULTS: We included 20 eligible studies (2026 patients). The pooled proportion of patients with management change was 53% (95% confidence interval [CI] 46-60) in patients with BCR and 51% (95% CI, 34-67) in patients with early BCR (prostate-specific antigen [PSA] <0.5 ng/mL). The pooled positron-emission tomography-positive rate in patients with BCR was 68% (95% CI 59-78). Fourteen studies reported management change, with most changes being intermodal in nature (42%, vs 17% intramodal change). CONCLUSIONS: The use of 68 Ga-PSMA tracers altered the management of more than half of PCa patients with BCR, including those with early BCR. 68 Ga-PSMA tracers might be used to guide individualized treatment in patients with BCR, particularly those with early BCR.
引用
- Diao W, Cao Y, Su D, et al. Impact of 68 Gallium prostate-specific membrane antigen tracers on the management of patients with prostate cancer who experience biochemical recurrence. BJU Int. 2020. PMID: 32979229. doi:10.1111/bju.15257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。